IV Ketamine

Outcomes

As a result of participating in this activity, learners will be better able to:

• Implement safety protocols
• Identify patients who may benefit from IV ketamine for chronic, refractory pain. 
• Determine the dosing rate for IV ketamine
• Improve outpatient practices

Accreditation & Designation

Release date: This activity was released 8/19/2022.

Termination date: The content of this activity remains eligible for CME Credit until 8/18/2025, unless reviewed or amended prior to this date.

Claiming Credit: Watch the entire presentation and complete the Improvement Plan/Evaluation.

Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Neurovations Education designates this other activity (blended learning) for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.

This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.

California Required CME on Pain Management and the Appropriate Treatment of the Terminally Ill
AB487 requires physicians licensed in California to complete a one-time CME activity for 12 hours of credits that addresses both pain management and the appropriate care and treatment of the terminally ill. This activity contributes to achievement of requirements with AB487.

Disclosure of Financial Relationships

Neither the presenter, reviewers nor any other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, any financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Additional Reading

• Ho, Ada Man Choi, Ben Kin Leung Cheung, and Alfreda Stadlin. "Pain response in heroin users: personality, abstinence, and modulation by benzodiazepines." Addictive Behaviors 36.12 (2011): 1361-1364.
• Carcoba, L. M., Contreras, A. E., Cepeda-Benito, A., & Meagher, M. W. (2011). Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. Journal of addictive diseases, 30(3), 258-270.
• Sang, C. N. (2000). NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. Journal of pain and symptom management, 19(1), 21-25.
• Zhao, J., Wang, Y., & Wang, D. (2018). The effect of ketamine infusion in the treatment of complex regional pain syndrome: a systemic review and meta-analysis. Current pain and headache reports, 22(2), 1-8.
• Brinck, E. C., Tiippana, E., Heesen, M., Bell, R. F., Straube, S., Moore, R. A., & Kontinen, V. (2018). Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database of Systematic Reviews, (12).
• Eldufani, J., Nekoui, A., & Blaise, G. (2018). Nonanesthetic effects of ketamine: a review article. The American journal of medicine, 131(12), 1418-1424.